EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical characteristics, risk factors, and mortality associated with Pseudomonas aeruginosa bacteremia

Hassan Itani, Lynn Kobeissi, Suha Kalash, Mohamad Mdaihly, Jad Ardakani, Zeina A Kanafani

The Journal of Infection in Developing Countries · 2026-10-31 · 20 (10) · 1511-1517

DOI: 10.3855/jidc.22599 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Pseudomonas aeruginosa bacteremia (PAB) is a major cause of morbidity and mortality, increasingly complicated by multidrug-resistant (MDR) strains which becomes a challenge to the treating physician. This study aimed to evaluate risk factors associated with PAB and its outcomes. Methodology: A retrospective cohort study was conducted at the American University of Beirut Medical Center (AUBMC), including 85 patients who were > 18 years of age with confirmed PAB during their hospital stay between 2017 and 2022. Results: Regarding resistance patterns, 8 (9.4%) patients had MDR strains and 19 (22.4%) were difficult to treat (DTR). Prior antibiotic use within 1 month was associated with the DTR infections (OR 4.97; p = 0.026). The in-hospital mortality rate was 51.8%. Male gender was associated with decreased mortality (OR 0.13; p = 0.036). Recent central line placement and Pitt bacteremia score were linked to increased mortality (OR 2.63; p = 0.028 and OR 51.71; p < 0.001, respectively). High-risk primary sources of infection such as central line, gastrointestinal, and respiratory systems had increased mortality compared with low-risk sources such as skin, abscess, and urinary tract (OR 25.96; p = 0.001). Conclusions: Prompt empirical therapy and identifying the infection source are critical in assessing severity of the infection in PAB. Pitt bacteremia score is a valuable predictor of outcomes. Rising DTR rates was linked to prior antibiotic use which highlights the importance of antimicrobial stewardship.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →